Effectiveness, safety, and biomarker analysis of sacituzumab govitecan in Chinese metastatic breast cancer: a multicenter real-world study.

Ther Adv Med Oncol · 2026 · PMC13018686 · PMID 41908795

Europe PMC DOI

hedged sentence

0.1150

closest p · 2.3× alpha

0.1150

boldest claim

The sentences

showed a trendp = 0.115not close (p > 0.1)

SG-based combination therapy showed a trend to improved PFS compared to monotherapy, both in TNBC (14.2 vs 4.6 months, HR = 0.51, p = 0.115) and HoR+HER2− patients (11.3 vs 5.8 months, HR = 0.35, p = 0.159; Supplemental Figure 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.